Navigation Links
First Human Implant of New Archus Orthopedics Facet Replacement System
Date:4/23/2008

-C completes our spinal stenosis product line and it is gratifying to see all three devices now in clinical use," said Jim Fitzsimmons, chairman and chief executive officer. While Archus will conduct clinical trials of the TFAS-C and other new products to gain marketing approval in the United States, the company's entire device family is already cleared for commercialization in the European Union. "We expect to complete marketing trials this year and plan to pursue a broad but controlled launch in Europe next year," said Fitzsimmons.

About Archus Orthopedics

Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. Archus has received venture capital funding from MPM Capital, InterWest Partners, Polaris Venture Partners and Johnson & Johnson Development Corporation, in cooperation with DePuy Spine.


'/>"/>
SOURCE Archus Orthopedics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...gnostic Value of Circulating Tumor Cells, RARITAN...prospective,clinical trial found the number of cir...of progression-free and overall survival among met... report published in the July 1,issue of the Journ... the US, the Netherlands, and the United,Kingdom, ...
(Date:7/24/2008)... 24 /PRNewswire-USNewswire/ -- Headlines claiming ...hole story. The small scale,preliminary study tha...production, is based on recollected intake of soyf.... "This study is confounded by many,issues, thus I...al of,caution," warned Dr. Tammy Hedlund, a resear...
(Date:7/23/2008)...st Approved Systemic Therapy to Treat the Disease ...RNewswire-FirstCall/ --,Bayer HealthCare Pharmaceu...X) today announced that The New England Journal of...onstrating that Nexavar(R) (sorafenib),tablets dec... patients with,unresectable hepatocellular carcino...
(Date:7/23/2008)... Some Areas of the Body Have Greater Concentration... /PRNewswire-USNewswire/ -- Fat removed,from the l...as found to be,an excellent source of stem cells, ...eas of the body, reports a Brazilian-based study i...the official medical journal of the,American Socie...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Soyfoods Do Not Impact Sperm Count 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Data Show Common Allergy Tests Are Not Interchangeable 18816 1Data Show Common Allergy Tests Are Not Interchangeable 18816 2Data Show Common Allergy Tests Are Not Interchangeable 18816 3Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Angiotech to participate in Bank of America Health Care Conference 5229 1Federal polar bear research critically flawed says study in INFORMS journal 3237 1Federal polar bear research critically flawed says study in INFORMS journal 3237 2
... Risk of Late Thrombosis is Minimized with Genous ... -- The efficacy of,OrbusNeich,s Genous(TM) Bio-en...g-eluting stents, while the risk of late thrombosi... an interim,analysis of post-marketing data presen...roPCR 2007 in Barcelona, Spain. , Collected from m...
... PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - ...the publication of a,review validating the utility...unction of the WW domain-containing oxidoreductase...nown involvement,in breast, prostate, lung, pancre...viewed article was published in the online,edition...
Other Medicine Technology:Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 2Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 4
(Date:7/25/2008)... firm represents Pickerington man who contracted E... Kroger store , Columbus,...onaheyohioinjurylawyers.com [The Donahey Law Firm... central Ohio, has filed a product liability lawsu...ainst The Kroger Co., in connection with an E. col...
(Date:7/24/2008)...ital facility on Sand Canyon Avenue , ...08 -- Hoag Memorial Hospital Presbyterian has reac...l Estate Investment Trust headquartered in Long Be... Sand Canyon Avenue near the 405 freeway in Irvine...d by Tenet Healthcare Corporation (NYSE: THC) as I...
(Date:7/24/2008)...stCall/ -- ev3 Inc. (Nasdaq:,EVVV) today announced...and,year-to-date financial results. ev3 will now r...ancial results on Monday, July 28, 2008, after reg... a conference call and webcast at 7:30 a.m.,Centra...9, 2008. ev3,management will review its second qua...
(Date:7/24/2008)...ine Annual Report Experience it at http:/...f., July 24 /PRNewswire/ -- Are you an e-patient?,...users go online for,health information. Thanks to ...re personal health experiences, shop for health ca...Go to http://SutterHealth.org/annualreport ,and y...
Breaking Medicine News(10 mins):Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4
...h world but the death rate from it is falling due ...ers from the University of Southern Denmark carrie...0,000 people between 1993 and 1999. While the prop... by around three percent annually during the six-y...
...it suicide than other people, scientists said on F...s of more than 20,000 same-sex twins who died betw...ide with the wider population. They found that the...ardless of their sex.// The findings came as a sur...
...ck, the most important thing they can do to increa...to their heart is to get help as soon as possible....tional Heart, Lung, and Blood Institute, many peop...y experience heart attack symptoms because they do...
...hown to boost vitamin D levels and now researchers...r sun exposure during childhood and early adolesce...sclerosis, according to the study. Australian inve...which is located at high latitude and has a high p...
Other Medicine News:Health News:Recognize Heart Attack Signs 2
...Ovulation Predicting Test is a qualitative immunoa...e (hLH) in human urine to predict the occurrence o...on of human luteinizing hormone (hLH). Usually, ar...rief, significant rapid increase called the "LH su...
The Shandon Cryotome SME Cryostat model is a sophisticated, top of the line cryostat that combines automated electronic advance and hands-free sectioning with fully independent specimen temperature c
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
The Shandon Varistain Gemini is designed for high throughput, precision, safety, durability and ultimate flexibility in histology and cytology staining applications. It features load-on-demand multip
Medicine Products: